[go: up one dir, main page]

MX2023002982A - Inhibidores de la interaccion de menina-leucemia de linaje mixto. - Google Patents

Inhibidores de la interaccion de menina-leucemia de linaje mixto.

Info

Publication number
MX2023002982A
MX2023002982A MX2023002982A MX2023002982A MX2023002982A MX 2023002982 A MX2023002982 A MX 2023002982A MX 2023002982 A MX2023002982 A MX 2023002982A MX 2023002982 A MX2023002982 A MX 2023002982A MX 2023002982 A MX2023002982 A MX 2023002982A
Authority
MX
Mexico
Prior art keywords
menin
inhibitors
mll
interaction
mll interaction
Prior art date
Application number
MX2023002982A
Other languages
English (en)
Inventor
Jing Yuan
Stephan D Parent
David A Claremon
Stephen D Lotesta
Andrew Marcus
Travis L Houston
Chengguo Dong
Yi Fan
Suresh B Singh
Lawrence Wayne Dillard
Linghang Zhuang
Salvacion Cacatian
Angel Morales-Ramos
Shankar Venkatraman
Yajun Zheng
Lanqui Jia
Original Assignee
Vitae Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vitae Pharmaceuticals Llc filed Critical Vitae Pharmaceuticals Llc
Publication of MX2023002982A publication Critical patent/MX2023002982A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La presente invención se refiere a inhibidores de la interacción de menina con MLL y proteínas de fusión de MLL, composiciones farmacéuticas que contienen los mismos, y su uso en el tratamiento de cáncer y otras enfermedades mediadas por la interacción de menina-MLL.
MX2023002982A 2016-06-10 2018-12-07 Inhibidores de la interaccion de menina-leucemia de linaje mixto. MX2023002982A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662348496P 2016-06-10 2016-06-10

Publications (1)

Publication Number Publication Date
MX2023002982A true MX2023002982A (es) 2023-04-10

Family

ID=59325631

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2018015252A MX381228B (es) 2016-06-10 2017-06-08 Inhibidores de la interacción de menina-leucemia de linaje mixto.
MX2021003939A MX2021003939A (es) 2016-06-10 2018-12-07 Inhibidores de la interaccion de menina-leucemia de linaje mixto.
MX2023002982A MX2023002982A (es) 2016-06-10 2018-12-07 Inhibidores de la interaccion de menina-leucemia de linaje mixto.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2018015252A MX381228B (es) 2016-06-10 2017-06-08 Inhibidores de la interacción de menina-leucemia de linaje mixto.
MX2021003939A MX2021003939A (es) 2016-06-10 2018-12-07 Inhibidores de la interaccion de menina-leucemia de linaje mixto.

Country Status (21)

Country Link
US (4) US10683302B2 (es)
EP (2) EP3468966B1 (es)
JP (4) JP7007302B2 (es)
KR (2) KR20250079083A (es)
CN (1) CN109743875B (es)
AU (3) AU2017278950B2 (es)
BR (1) BR122024002146A2 (es)
CA (1) CA3024180A1 (es)
CY (1) CY1124834T1 (es)
DK (1) DK3468966T3 (es)
ES (1) ES2831084T3 (es)
HR (1) HRP20201771T1 (es)
HU (1) HUE051451T2 (es)
IL (4) IL298381B2 (es)
LT (1) LT3468966T (es)
MX (3) MX381228B (es)
PL (1) PL3468966T3 (es)
PT (1) PT3468966T (es)
SI (1) SI3468966T1 (es)
WO (1) WO2017214367A1 (es)
ZA (1) ZA201900150B (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10246464B2 (en) 2014-09-09 2019-04-02 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
WO2016197027A1 (en) 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
AR104020A1 (es) 2015-06-04 2017-06-21 Kura Oncology Inc Métodos y composiciones para inhibir la interacción de menina con proteínas mill
MX387806B (es) 2016-03-16 2025-03-19 Kura Oncology Inc Inhibidores biciclicos con puente sustituidos de menina-mll y metodos de uso
SMT202300273T1 (it) 2016-03-16 2023-09-06 Kura Oncology Inc Derivati di tieno[2,3–d]pirimidina sostituiti come inibitori di menina–mll e metodi d’uso
MX384087B (es) 2016-05-02 2025-03-14 Univ Michigan Regents Piperidinas como inhibidores de menina.
PT3468966T (pt) 2016-06-10 2020-11-10 Vitae Pharmaceuticals Llc Inibidores da interação menina-mll
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
HUE053907T2 (hu) 2016-09-14 2021-07-28 Janssen Pharmaceutica Nv A menin-MLL kölcsönhatás spiro-biciklusos inhibitorai
CN109715634B (zh) 2016-09-14 2022-09-27 詹森药业有限公司 Menin-mll相互作用的稠合二环抑制剂
AU2017376599B2 (en) 2016-12-15 2021-10-07 Janssen Pharmaceutica Nv Azepane inhibitors of menin-MLL interaction
WO2018175746A1 (en) 2017-03-24 2018-09-27 Kura Oncology, Inc. Methods for treating hematological malignancies and ewing's sarcoma
CA3058448A1 (en) 2017-03-31 2018-10-04 The Regents Of The University Of Michigan Piperidines as covalent menin inhibitors
WO2018190350A1 (ja) * 2017-04-10 2018-10-18 三井化学アグロ株式会社 ピリドン化合物およびそれを有効成分とする農園芸用殺菌剤
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
TW201920170A (zh) 2017-09-20 2019-06-01 美商庫拉腫瘤技術股份有限公司 經取代之menin-mll 抑制劑及使用方法
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
KR20200101389A (ko) * 2017-12-20 2020-08-27 얀센 파마슈티카 엔.브이. 메닌-mll 상호작용의 엑소-아자 스피로 억제제
WO2019189732A1 (ja) 2018-03-30 2019-10-03 大日本住友製薬株式会社 光学活性な架橋型環状２級アミン誘導体
JP6671574B1 (ja) * 2018-08-27 2020-03-25 大日本住友製薬株式会社 光学活性なアザビシクロ環誘導体
US10815241B2 (en) 2018-08-27 2020-10-27 Sumitomo Dainippon Pharma Co., Ltd. Optically active azabicyclo ring derivative
CN111285875B (zh) * 2018-12-06 2023-02-03 苏州信诺维医药科技股份有限公司 一种杂环化合物、其应用及含其的药物组合物
KR102912146B1 (ko) 2018-12-06 2026-01-14 다이이찌 산쿄 가부시키가이샤 시클로알칸-1,3-디아민 유도체
AU2019417833B2 (en) 2018-12-31 2024-11-07 Biomea Fusion, Inc. Irreversible inhibitors of menin-MLL interaction
WO2020142559A1 (en) * 2018-12-31 2020-07-09 Biomea Fusion, Llc Inhibitors of menin-mll interaction
UY38906A (es) 2019-10-09 2021-05-31 Novartis Ag Compuestos 2- derivados de azaspiro[3,4]octano como agonistas de m4 y composiciones de los mismos
JOP20220084A1 (ar) * 2019-10-09 2023-01-30 Novartis Ag مشتقات 5-أوكسا- 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4
UY38988A (es) * 2019-12-19 2021-06-30 Janssen Pharmaceutica Nv Derivados espiráncos sustituidos de cadena lineal
JP7454520B2 (ja) * 2020-02-26 2024-03-22 住友ファーマ株式会社 光学活性なアザビシクロ環誘導体からなる医薬
CN111297863B (zh) * 2020-03-30 2021-06-25 四川大学华西医院 menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用
WO2021207335A1 (en) * 2020-04-07 2021-10-14 Syndax Pharmaceuticals, Inc. Combinations of menin inhibitors and cyp3a4 inhibitors and methods of use thereof
EP4232020A4 (en) * 2020-10-21 2024-08-07 Kura Oncology, Inc. Treatment of hematological malignancies with inhibitors of menin
CN114516873A (zh) * 2020-11-18 2022-05-20 苏州优理生物医药科技有限公司 一种螺环类化合物、包含其药物组合物及其应用
RU2752079C1 (ru) * 2020-12-01 2021-07-22 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (Е)-(6-(2-гидроксифенил)-2-иминио-4,7,8-триоксо-1,3-дифенил-1,3,6-триазаспиро[4.4]нонан-9-илиден)(4-метоксифенил)метаноат, обладающий противомикробной активностью, и способ его получения
KR20240005747A (ko) 2021-05-08 2024-01-12 얀센 파마슈티카 엔브이 치환된 스피로 유도체
WO2022237626A1 (en) 2021-05-08 2022-11-17 Janssen Pharmaceutica Nv Substituted spiro derivatives
KR20240006631A (ko) * 2021-05-11 2024-01-15 얀센 파마슈티카 엔브이 조합 요법
KR20240006638A (ko) * 2021-05-11 2024-01-15 얀센 파마슈티카 엔브이 조합 요법
BR112023023463A2 (pt) 2021-05-14 2024-01-30 Syndax Pharmaceuticals Inc Inibidores da interação menin-mll
MX2023014347A (es) 2021-06-01 2023-12-13 Janssen Pharmaceutica Nv Derivados de fenil-1h-pirrolo[2,3-c]piridina sustituidos.
EP4347600A1 (en) 2021-06-03 2024-04-10 JANSSEN Pharmaceutica NV Pyridazines or 1,2,4-triazines substituted by spirocyclic amines
WO2022253309A1 (zh) * 2021-06-03 2022-12-08 首药控股(北京)股份有限公司 取代的杂环化合物及其应用
WO2022257047A1 (en) * 2021-06-09 2022-12-15 Acerand Therapeutics (Hong Kong) Limited Diazaspirobicylic compounds as protein-protein interaction inhibitors and applications thereof
PE20240923A1 (es) 2021-06-17 2024-04-30 Janssen Pharmaceutica Nv Sal de besilato de (r)-n-etil-5-fluoro-n-isopropil-2-((5-(2-(6-((2-metoxietil) (metil)amino)-2-metilhexan-3-il)-2,6-diazaspiro[3.4]octan-6-il)-1,2,4-triazin-6-il)oxi)benzamida para el tratamiento de enfermedades tales como el cancer
WO2023011446A1 (zh) * 2021-08-04 2023-02-09 成都苑东生物制药股份有限公司 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途
CN115515958B (zh) * 2021-08-04 2023-09-29 成都苑东生物制药股份有限公司 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途
CA3228627A1 (en) 2021-08-11 2023-02-16 Thomas Butler Covalent inhibitors of menin-mll interaction for diabetes mellitus
AU2022331496A1 (en) 2021-08-20 2024-02-29 Biomea Fusion, Inc. Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cancer
CN113769098B (zh) * 2021-09-22 2022-09-30 中国医学科学院肿瘤医院深圳医院 MLL-menin抑制剂组合物在制备抗肝癌药物中的应用
US20240317748A1 (en) * 2021-12-03 2024-09-26 Bionova Pharmaceuticals (Shanghai) Limited Carbonyl substituted diazaspiro compounds and its use
AU2022424212B2 (en) * 2021-12-31 2025-08-28 Hitgen Inc. Menin inhibitor and use thereof
WO2023178035A1 (en) 2022-03-14 2023-09-21 Slap Pharmaceuticals Llc Multicyclic compounds
CN117069719A (zh) * 2022-08-17 2023-11-17 烨辉医药科技(上海)有限公司 二氮杂螺环-哒嗪化合物及其用途
PE20251079A1 (es) * 2022-09-02 2025-04-10 Hutchmed Ltd Compuestos de triazina y usos de los mismos
CN120529900A (zh) 2022-11-24 2025-08-22 奥莱松基因组股份有限公司 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合
CN118271341A (zh) * 2022-12-30 2024-07-02 成都先导药物开发股份有限公司 Menin抑制剂及其用途
WO2024155710A1 (en) 2023-01-18 2024-07-25 Biomea Fusion, Inc. Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6- yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2-pyridinecarboxamide as a covalent inhibitor of menin-mll interaction
WO2024213101A1 (zh) * 2023-04-13 2024-10-17 首药控股(北京)股份有限公司 取代的杂环化合物
CN118994033B (zh) * 2023-05-17 2025-09-16 成都先导药物开发股份有限公司 一种sdnx-5613的合成方法及其中间体化合物
CN116969891A (zh) * 2023-07-28 2023-10-31 杭州国瑞生物科技有限公司 一种7-甲基-5-醛基-1h-吲唑的合成方法
WO2025049521A2 (en) * 2023-08-28 2025-03-06 Syndax Pharmaceuticals, Inc. Aryl ether analogs as inhibitors of the menin-mll interaction
WO2025059366A1 (en) * 2023-09-13 2025-03-20 Kumquat Biosciences Inc. Ras inhibitors
WO2025097148A2 (en) 2023-11-04 2025-05-08 Syndax Pharmaceuticals, Inc. Salts and polymorphic forms of menin inhibitors and pharmaceutical compositions thereof
WO2025188611A1 (en) * 2024-03-04 2025-09-12 Dana-Farber Cancer Institute, Inc. Chemical matters for targeting leukemic complex proteins

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US5820915A (en) 1996-06-27 1998-10-13 Bioavailability Systems, L.L.C. Method for the preparation of a first-pass effective citrus-derived substance and product thereof
US6124477A (en) 1996-06-27 2000-09-26 Bioavailability Systems, Llc Anti-first-pass effect compounds
US5990154A (en) 1997-05-30 1999-11-23 Bioavailability Systems, L.L.C. Anti-first-pass effect compounds and citrus extract
US6248776B1 (en) 1997-08-26 2001-06-19 Bioavailability Systems, L.L.C. Anti-first-pass effect compounds
US20040058982A1 (en) 1999-02-17 2004-03-25 Bioavailability System, Llc Pharmaceutical compositions
US6063809A (en) 1997-08-26 2000-05-16 Bioavailability Systems, Llc Anti-first-pass effect compounds
US5993887A (en) 1998-06-29 1999-11-30 Bioavailability Systems, L.L.C. Safe citrus juice and process for preparation
WO2004037827A1 (en) 2000-10-20 2004-05-06 Bioavailability Systems, Llc Synthesis of spiro ortho esters, spiro ortho carbonates, and intermediates
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
EP1732891A4 (en) 2004-03-11 2009-05-06 Sequoia Pharmaceuticals Inc RESISTANT PREVENTIVE INHIBITORS FOR RETROVIRAL PROTEASES
CA2566340C (en) 2004-05-07 2014-05-06 Sequoia Pharmaceuticals, Inc. Resistance-repellent retroviral protease inhibitors
US20090281114A1 (en) 2008-05-08 2009-11-12 Fabre-Kramer Pharmaceuticals, Inc. Indolylalkyl derivatives of pyrimidinylpiperazine and metabolites thereof for treatment of anxiety, depression, and sexual dysfunction
CL2009001152A1 (es) 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
KR20190011343A (ko) 2011-06-10 2019-02-01 메르크 파텐트 게엠베하 Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물의 조성물 및 제조방법
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
KR20140040594A (ko) 2012-09-26 2014-04-03 아로그 파마슈티칼스, 엘엘씨 돌연변이체 c-kit의 억제 방법
AU2014249233A1 (en) 2013-03-13 2015-09-24 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
WO2015108940A2 (en) 2014-01-14 2015-07-23 The Trustees Of The University Of Pennsylvania Tailored combinatorial epigenetic therapies for p53 gain-of-function tumors
WO2015191701A1 (en) * 2014-06-10 2015-12-17 The Trustees Of The University Of Pennsylvania Scaffolds for inhibitors of menin-mll interactions
US20170232030A1 (en) 2014-08-13 2017-08-17 Epizyme, Inc. Combination therapy for treating cancer
CN105732636B (zh) 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
WO2016197027A1 (en) 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
EP3394064A1 (en) 2015-12-22 2018-10-31 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction
ES3044036T3 (en) 2016-01-26 2025-11-26 Memorial Sloan Kettering Cancer Center Targeting chromatin regulators for inhibiting leukemogenic gene expression in npm1
MX387806B (es) 2016-03-16 2025-03-19 Kura Oncology Inc Inhibidores biciclicos con puente sustituidos de menina-mll y metodos de uso
MX384087B (es) 2016-05-02 2025-03-14 Univ Michigan Regents Piperidinas como inhibidores de menina.
EP4483875A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
PT3468966T (pt) 2016-06-10 2020-11-10 Vitae Pharmaceuticals Llc Inibidores da interação menina-mll
CN110325533B (zh) 2016-09-16 2025-11-04 生命医药有限责任公司 Menin-mll相互作用的抑制剂
WO2018175746A1 (en) 2017-03-24 2018-09-27 Kura Oncology, Inc. Methods for treating hematological malignancies and ewing's sarcoma
KR20200101389A (ko) 2017-12-20 2020-08-27 얀센 파마슈티카 엔.브이. 메닌-mll 상호작용의 엑소-아자 스피로 억제제
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
JP2021519785A (ja) 2018-03-30 2021-08-12 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン 共有結合性メニン阻害剤としてのピペリジン化合物
EP3849606A4 (en) 2018-09-13 2022-06-29 Merck Sharp & Dohme Corp. Combination of pd-1 antagonist and lag3 antagonist for treating non-microsatellite instablity-high/proficient mismatch repair colorectal cancer
JP2022503792A (ja) 2018-09-26 2022-01-12 クラ オンコロジー，インク． メニン阻害剤を用いた血液悪性腫瘍の処置
AU2019417833B2 (en) 2018-12-31 2024-11-07 Biomea Fusion, Inc. Irreversible inhibitors of menin-MLL interaction
WO2021207335A1 (en) 2020-04-07 2021-10-14 Syndax Pharmaceuticals, Inc. Combinations of menin inhibitors and cyp3a4 inhibitors and methods of use thereof
CA3214990A1 (en) 2021-05-12 2022-11-17 Gerard M. Mcgeehan Combinations for treatment of cancer
BR112023023463A2 (pt) 2021-05-14 2024-01-30 Syndax Pharmaceuticals Inc Inibidores da interação menin-mll
CA3228627A1 (en) 2021-08-11 2023-02-16 Thomas Butler Covalent inhibitors of menin-mll interaction for diabetes mellitus
KR20240121720A (ko) 2021-12-15 2024-08-09 다나-파버 캔서 인스티튜트 인크. 메닌-mll 후성유전학적 복합체 파괴에 의한 위장관 기질 종양(gist)의 치료 표적화

Also Published As

Publication number Publication date
IL263586B (en) 2021-06-30
MX381228B (es) 2025-03-12
US20230174541A1 (en) 2023-06-08
NZ748203A (en) 2025-06-27
US12312359B2 (en) 2025-05-27
JP2019517548A (ja) 2019-06-24
DK3468966T3 (da) 2020-11-09
IL283267A (en) 2021-07-29
RU2019100040A (ru) 2020-07-13
US20250326764A1 (en) 2025-10-23
EP3468966A1 (en) 2019-04-17
IL283267B2 (en) 2023-04-01
CA3024180A1 (en) 2017-12-14
EP3468966B1 (en) 2020-08-05
US20210053974A1 (en) 2021-02-25
SI3468966T1 (sl) 2021-03-31
US11479557B2 (en) 2022-10-25
CN109743875B (zh) 2022-04-29
EP3805215A1 (en) 2021-04-14
ES2831084T3 (es) 2021-06-07
KR20220123727A (ko) 2022-09-08
BR122024002146A2 (pt) 2024-03-05
JP7461390B2 (ja) 2024-04-03
KR20190017012A (ko) 2019-02-19
CY1124834T1 (el) 2022-07-22
US10683302B2 (en) 2020-06-16
JP7007302B2 (ja) 2022-01-24
PL3468966T3 (pl) 2021-04-06
MX2018015252A (es) 2019-04-25
LT3468966T (lt) 2021-02-25
PT3468966T (pt) 2020-11-10
IL283267B (en) 2022-12-01
IL298381A (en) 2023-01-01
CN109743875A (zh) 2019-05-10
AU2017278950B2 (en) 2021-07-29
JP2024045176A (ja) 2024-04-02
IL298381B1 (en) 2025-08-01
KR102436430B1 (ko) 2022-08-24
MX2021003939A (es) 2021-05-27
IL263586A (en) 2019-01-31
ZA201900150B (en) 2023-04-26
HUE051451T2 (hu) 2021-03-01
RU2019100040A3 (es) 2020-07-15
AU2017278950A1 (en) 2019-01-03
JP2025113339A (ja) 2025-08-01
HRP20201771T1 (hr) 2021-02-19
US20190144459A1 (en) 2019-05-16
IL321844A (en) 2025-08-01
AU2021258089A1 (en) 2021-11-25
KR20250079083A (ko) 2025-06-04
AU2021258089B2 (en) 2024-01-25
IL298381B2 (en) 2025-12-01
BR112018075260A2 (pt) 2019-03-12
WO2017214367A1 (en) 2017-12-14
JP2022058514A (ja) 2022-04-12
AU2024202700A1 (en) 2024-05-16

Similar Documents

Publication Publication Date Title
MX2022013841A (es) Inhibidores de la interaccion de menina-mll.
MX2023002982A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
MX2018007703A (es) Inhibidores de la interaccion de menina-linaje leucemico mixto.
PH12019502810A1 (en) Bicyclic heterocycles as fgfr inhibitors
PH12017501483A1 (en) Bicyclic heterocycles as fgfr4 inhibitors
PH12018502429A1 (en) Antibody molecules for cancer treatment
PH12017501481B1 (en) Bicyclic heterocycles as fgfr inhibitors
EP3603661A3 (en) Rna containing composition for treatment of tumor diseases
PH12016501139A1 (en) Bicyclic heterocycle compounds and their uses in therapy
EP4620519A3 (en) Methods and compositions relating to chondrisomes from blood products
EA201690159A1 (ru) Способы и композиции для лечения рака
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
EA202090270A1 (ru) Новые замещенные производные ксантина
MX2020000135A (es) Nuevos compuestos de quinolinona.
TW201613926A (en) Inhibitors of bruton's tyrosine kinase
PH12017501693A1 (en) Compositions for the treatment of kidney and/or liver diseases
EA202190877A1 (ru) Бициклические гетероциклы в качестве ингибиторов fgfr
HK1246796A1 (en) Bicyclic heterocycles as fgfr4 inhibitors